AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
Log in

NASDAQ:AXSMAxsome Therapeutics Stock Price, Forecast & News

$75.74
-1.25 (-1.62 %)
(As of 06/2/2020 02:43 PM ET)
Add
Compare
Today's Range
$73.50
Now: $75.74
$78.37
50-Day Range
$56.15
MA: $80.18
$98.69
52-Week Range
$13.64
Now: $75.74
$109.94
Volume238,659 shs
Average Volume620,100 shs
Market Capitalization$2.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.14
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Read More
Axsome Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.18 per share

Profitability

Net Income$-68,350,000.00

Miscellaneous

Employees29
Market Cap$2.81 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

How has Axsome Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXSM shares have increased by 2.8% and is now trading at $75.7413. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Axsome Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axsome Therapeutics.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Axsome Therapeutics.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics Inc (NASDAQ:AXSM) released its quarterly earnings data on Friday, May, 8th. The company reported ($0.88) EPS for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.28. View Axsome Therapeutics' earnings history.

What price target have analysts set for AXSM?

9 brokerages have issued twelve-month price targets for Axsome Therapeutics' stock. Their forecasts range from $48.00 to $210.00. On average, they expect Axsome Therapeutics' share price to reach $143.56 in the next twelve months. This suggests a possible upside of 89.5% from the stock's current price. View analysts' price targets for Axsome Therapeutics.

Has Axsome Therapeutics been receiving favorable news coverage?

Media headlines about AXSM stock have trended positive on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Axsome Therapeutics earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAxsome Therapeutics.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 3,590,000 shares, a drop of 14.9% from the April 30th total of 4,220,000 shares. Based on an average daily volume of 986,200 shares, the days-to-cover ratio is presently 3.6 days. Approximately 12.5% of the company's stock are sold short. View Axsome Therapeutics' Current Options Chain.

Who are some of Axsome Therapeutics' key competitors?

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Micron Technology (MU), Viking Therapeutics (VKTX), AbbVie (ABBV) and Advanced Micro Devices (AMD).

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the following people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)
  • Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)
  • Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)
  • Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)
  • Joseph Debrah-Afful, Director of Fin.

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.08%), RA Capital Management L.P. (5.14%), Alethea Capital Management LLC (2.67%), VR Adviser LLC (2.18%), State Street Corp (1.78%) and Invesco Ltd. (1.78%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View institutional ownership trends for Axsome Therapeutics.

Which major investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Cormorant Asset Management LP, UBS Group AG, Janney Montgomery Scott LLC, Driehaus Capital Management LLC, Chartwell Investment Partners LLC, Blair William & Co. IL, and Baldwin Brothers Inc. MA. View insider buying and selling activity for Axsome Therapeutics.

Which major investors are buying Axsome Therapeutics stock?

AXSM stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., VR Adviser LLC, Pictet Asset Management Ltd., Fairmount Funds Management LLC, BlackRock Inc., Two Sigma Advisers LP, Nuveen Asset Management LLC, and Sofinnova Investments Inc.. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, and Nick Pizzie. View insider buying and selling activity for Axsome Therapeutics.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $75.74.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $2.81 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.

What is Axsome Therapeutics' official website?

The official website for Axsome Therapeutics is axsome.com.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at 212-332-3241.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.